Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,948,122 | 4,864,501 | 5,746,586 | 4,974,131 | 7,562,286 |
| Marketable Securities | 149,288 | 294,416 | 229,910 | 142,781 | 225,215 |
| Receivables | 5,044,528 | 5,537,091 | 5,763,859 | 6,114,508 | 6,446,956 |
| Inventories | 7,299,782 | 6,583,730 | 6,864,840 | 7,141,834 | 7,593,187 |
| Other current assets | 1,303,160 | 1,151,482 | 1,163,245 | 1,258,016 | 1,255,767 |
| TOTAL | $17,744,880 | $18,431,220 | $19,768,440 | $19,631,270 | $23,083,410 |
| Non-Current Assets | |||||
| PPE Net | 12,515,090 | 11,760,550 | 12,674,350 | 13,131,330 | 14,086,920 |
| Investments And Advances | 2,803,542 | 2,623,230 | 3,065,515 | 2,938,374 | 2,938,184 |
| Intangibles | 67,046,810 | 60,042,620 | 66,108,150 | 68,981,990 | 73,214,000 |
| Other Non-Current Assets | 3,177,038 | 3,025,780 | 3,423,245 | 3,620,826 | 3,961,836 |
| TOTAL | $85,542,480 | $77,452,180 | $85,271,260 | $88,672,520 | $94,200,940 |
| Total Assets | $103,287,400 | $95,883,410 | $105,039,700 | $108,303,800 | $117,284,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,513,040 | 2,641,335 | 4,091,242 | 2,170,607 | 1,815,538 |
| Accounts payable and accrued liabilities | 4,804,324 | 2,705,874 | 2,798,035 | 3,267,557 | 4,595,043 |
| Other current liabilities | 9,329,401 | 9,193,797 | 8,966,211 | 9,326,656 | 10,898,250 |
| TOTAL | $18,366,360 | $15,881,340 | $17,220,380 | $16,685,450 | $19,097,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 29,916,280 | 27,795,680 | 30,012,600 | 33,266,750 | 36,858,620 |
| Other Non-Current Liabilities | 5,977,545 | 5,593,449 | 6,116,291 | 6,190,280 | 6,727,122 |
| TOTAL | $37,896,430 | $36,148,920 | $39,482,190 | $42,974,490 | $47,604,020 |
| Total Liabilities | $56,262,780 | $52,030,260 | $56,702,580 | $59,659,930 | $66,701,010 |
| Shareholders' Equity | |||||
| Common Shares | 12,404,950 | 11,901,970 | 12,069,580 | 12,907,330 | 14,918,740 |
| Retained earnings | 11,404,480 | 10,704,810 | 11,017,440 | 11,240,180 | 13,169,470 |
| Other shareholders' equity | 11,163,800 | 9,802,900 | 13,764,180 | 12,344,850 | 8,318,180 |
| TOTAL | $47,024,570 | $43,853,140 | $48,337,120 | $48,643,850 | $50,583,360 |
| Total Liabilities And Equity | $103,287,350 | $95,883,400 | $105,039,700 | $108,303,780 | $117,284,370 |